Treatment for neovascular age‐related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register

Westborg, Inger; Rosso, Aldana; Albrecht, Susanne; Karlsson, Niklas; Lövestam-Adrian, Monica

doi:10.1111/aos.13539

Cited by 31 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our finding that the number of IVT was not related to improved BCVA is in line with a previous study (Westborg et al. ) and underscores that the individual need for IVT is variable.…”

Section: Discussionsupporting

confidence: 93%

“…In establishing the best management for patients with nAMD, timely diagnosis and treatment could be more important than the choice of treatment regime and drug. Our finding that the number of IVT was not related to improved BCVA is in line with a previous study (Westborg et al 2017) and underscores that the individual need for IVT is variable.…”

Section: Prognostic Factorssupporting

confidence: 92%

“…In a Swedish nationwide study (Westborg et al. ), the BCVA loss was only 1 ETDRS letter after 7 years, but their patients had lower mean baseline BCVA of 54.3 letters compared with 63.0 in our study and therefore, less ceiling effect. A Norwegian study (Berg et al.…”

Section: Discussioncontrasting

confidence: 58%

“…; Westborg et al. ). The lower discontinuation rate in more recent eyes could be a reflection of the better presenting BCVA, fewer intractable cases or a change in the management of the patients.…”

Section: Discussionmentioning

confidence: 98%

See 3 more Smart Citations

Real‐world 10‐year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age‐related macular degeneration

Brynskov

Munch

Larsen

et al. 2019

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose To report 10‐year, real‐world experiences with intravitreal therapy (IVT) using vascular endothelial growth factor inhibitors for neovascular age‐related macular degeneration (nAMD). Methods Retrospective single‐centre review of IVT‐log 2007–2019 with a treatment‐as‐needed regimen and ETDRS visual acuity charts. Results The 4,678 treatment‐naïve eyes of 3,668 patients received a mean of 5.4 IVT in the first year and 4.0–4.3 IVT yearly thereafter. Baseline mean best corrected visual acuity (BCVA) was 57.9 (±16.4) letters (6/18) that improved a mean +2.1 (±0.2) letters at the first follow‐up visit and gradually declined to −5.0 (±2.2) letters after 10 years. At baseline, there were 29% with BCVA ≥6/12. This proportion increased to 31–37% until year 9. There were 8% with BCVA loss of ≥3 lines at the first follow‐up visit increasing to 34% after 10 years. Poorer baseline BCVA was associated with larger increase in BCVA (p < 0.0001, multiple linear regression). The 2,566 (55%) discontinued eyes had a mean baseline BCVA of 56.9 (±16.4) letters compared with 61.5 (±15.9) letters for eyes remaining in treatment. In year 0–7, the discontinued eyes lost an additional mean 2–4 letters (last observation carried forward) but were similar thereafter. There were 12.6% (74 of 585 eligible eyes) that were still in treatment after 10 years. At baseline, 10% had bilateral nAMD. Of patients with unilateral presentation, 17% had received fellow‐eye IVT after 5 years. Conclusion A treatment‐as‐needed regimen stabilized BCVA in active nAMD up to 10 years in most eyes. Baseline BCVA was the most important prognostic factor.

show abstract

“…Our finding that the number of IVT was not related to improved BCVA is in line with a previous study (Westborg et al. ) and underscores that the individual need for IVT is variable.…”

Section: Discussionsupporting

confidence: 93%

Section: Prognostic Factorssupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 58%

Section: Discussionmentioning

confidence: 98%

See 2 more Smart Citations

Real‐world 10‐year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age‐related macular degeneration

Brynskov

Munch

Larsen

et al. 2019

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Since their introduction, patients have benefitted from improvements in both functional and anatomical outcomes over several years, while the number of patients diagnosed as legally blind has decreased (Berg et al 2017;Westborg et al 2017). Since their introduction, patients have benefitted from improvements in both functional and anatomical outcomes over several years, while the number of patients diagnosed as legally blind has decreased (Berg et al 2017;Westborg et al 2017).…”

Section: Introductionmentioning

confidence: 99%

Predictors of visual outcomes in patients with neovascular age‐related macular degeneration treated with anti‐vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies

Lanzetta

Cruess

Cohen

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

Das Hamburger Register für intravitreale Injektionstherapien (QIVOM)

Wolfram

Schargus

2021

Ophthalmologe

View full text Add to dashboard Cite

Zusammenfassung Hintergrund Intravitreale operative Medikamenteneingaben (IVOM) gehören zu den häufigsten medizinischen Prozeduren überhaupt mit ca. 1,5 Mio. Eingriffen in Deutschland pro Jahr. Für diese enorme Versorgungsaufgabe gibt es nur wenige empirische Daten über den Versorgungsprozess und seine klinische und subjektive Wirkung. Material und Methoden Es wird die Entwicklung und der Aufbau des Hamburger Registers für intravitreale Injektionstherapien (QIVOM) detailliert beschrieben. IVOM-Patienten der drei großen Augenkliniken Hamburgs (Asklepios Kliniken Nord-Hamburg und Barmbek, Universitätsklinikum Hamburg-Eppendorf) werden im Rahmen der Routineversorgung mit IVOM zur Studienteilnahme eingeladen. Es werden subjektive Patientenangaben zum Krankheits- und Behandlungserleben erhoben und diese mit den patientenbezogenen medizinischen Parametern elektronisch ergänzt, pseudonymisiert und in einer elektronischen Datenbank erfasst. Ergebnisse Von den ersten 162 Studienpatienten (Alter 41–95 Jahre) war die Behandlungsindikation bei 64% exsudative altersbedingte Makuladegeneration (AMD), bei 22% retinaler Venenverschluss und bei 11% diabetisches Makulaödem. Es ergibt sich ein heterogenes Bild der Erkrankungsschwere und der subjektiven Beeinträchtigung. Eine Sehschärfe von 0,5 und besser wiesen 31,8% der Patienten am behandelten Auge im Vergleich zu 79,1% am Partnerauge auf. Die größte praktische Einschränkung betraf die Lesefähigkeit, bei der über ein Drittel erhebliche Einschränkungen erlebte. Autofahren war immerhin für 62% möglich. Eine Verbesserung der Sehfähigkeit durch IVOM erreichten 45% der Patienten. Schlussfolgerung Die Datenerfassung von patientenseitigen Daten und medizinischer Versorgungsdaten aus den Kliniken stellt den großen Vorteil des neu geschaffenen Registers dar. Die Erweiterung der Datenbasis soll in Zukunft vielfältige weiterführende Erkenntnisse erbringen und zur Qualitätssicherung in der IVOM-Therapie beitragen.

show abstract

Treatment for neovascular age‐related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register

Abstract: The duration of symptoms before treatment decreased, while VA at baseline and after 1 year of treatment increased over the years and so did the number of injections. Long-term follow-up demonstrated stable VA.

Cited by 31 publications

References 27 publications

Real‐world 10‐year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age‐related macular degeneration

Real‐world 10‐year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age‐related macular degeneration

Predictors of visual outcomes in patients with neovascular age‐related macular degeneration treated with anti‐vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies

Das Hamburger Register für intravitreale Injektionstherapien (QIVOM)

Contact Info

Product

Resources

About